About this trial
Generating bespoke biosampling protocols for individual tumour specific translational projects is onerous, cumbersome and inefficient. This study aims to provide a broad platform to maximise the unique access to biopsy and resected tumour specimens available from cancer patients to provide a high-quality and efficient source of biosamples for specific translational projects. Access to historical FFPE samples and clinical data, as well as prospective fresh tissue samples, will allow interrogation of the underlying biology of these cancers. Matched pseudoanonymised clinical and radiological data will allow the development of rich high-yield datasets.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Biopsy or surgical resection as standard of care
Disqualifiers
Refusal or inability to consent, paediatric patients
Trial population
All patients with a solid organ malignancy requiring surgery or biopsy as part of their routine clinical care as decided by the specialist MDT.
Trial design
Cohort
Prospective
Treatments tested in this trial
Biosampling
Other interventionBiosampling of blood/tumour/adjacent normal tissue
Treatment groups
Trial outcomes
Primary outcomes
Biosample procurement
Patient biosamples delivered via platform
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Liverpool
Lead sponsor
Countess of Chester NHS Foundation Trust
Collaborator
Liverpool University Hospitals NHS Foundation Trust
Collaborator
Clatterbridge Centre for Oncology
Collaborator
Liverpool Heart and Chest Hospital NHS Foundation Trust
Collaborator
Liverpool Womens Hospital
Collaborator